Zangani Investor Community Announces Interview with ViRexx Medical Corporation President Marc Canton
Toronto, Canada, April 01, 2006 --(PR.com)-- Zangani Investor Community, an outsourced IR and Business Development firm specializing in small cap and micro cap companies announced today that it interviewed Marc Canton, President of ViRexx Medical Corporation (TSX:VIR; AMEX:REX), on March 23rd, 2006. Mr. Canton discussed latest stage drug candidates for treatment of ovarian cancer and chronic hepatitis B and C., as well as, the Company’s latest growth strategies and its listing on the AMEX.
To access the interview, please visit the Zangani Investor Community at:
www.zangani.com/virexx/2006-0323-rex . The interview is also available via Podcast at www.zangani.com or through the itunes music store.
About ViRexx Medical Corp.
ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B and C and solid tumors.
ViRexx's lead product candidate, OvaRex® MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of two Phase III clinical trials being funded by ViRexx's licensing partner Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation. For additional information about ViRexx, please see www.virexx.com.
About Zangani
Zangani is an outsourced IR and Business Development firm specializing in small cap and micro cap companies. They provide clients with an array of investor relations products, including customized company strategies, community forums, and webcasting which are tailored for small cap budgets. For more information please visit their website at http://www.zangani.com
Note: Except for the historical information contained herein, this press release contains, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Such statement may include, without limitation, statements with respect to the Company’s plans, objectives, expectations and intentions and other statements identified by words such as “may”, “could”, “would”, “should”, “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control).
L.G. Zangani, LLC provides financial public relations service to the Company. As such L.G. Zangani, LLC and/or its officers, agents and employees, receives remuneration for public relations and or other services in the form of monies, capital stock in the Company, warrants or options to purchase capital in the Company. The full disclaimer can be read here at http://www.zangani.com/disclaimer.
Contact:
Kevin Nally
Zangani Investor Community
9 Main Street
Flemington, NJ 08822
office@zangani.com
http://www.zangani.com
###
To access the interview, please visit the Zangani Investor Community at:
www.zangani.com/virexx/2006-0323-rex . The interview is also available via Podcast at www.zangani.com or through the itunes music store.
About ViRexx Medical Corp.
ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B and C and solid tumors.
ViRexx's lead product candidate, OvaRex® MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of two Phase III clinical trials being funded by ViRexx's licensing partner Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation. For additional information about ViRexx, please see www.virexx.com.
About Zangani
Zangani is an outsourced IR and Business Development firm specializing in small cap and micro cap companies. They provide clients with an array of investor relations products, including customized company strategies, community forums, and webcasting which are tailored for small cap budgets. For more information please visit their website at http://www.zangani.com
Note: Except for the historical information contained herein, this press release contains, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Such statement may include, without limitation, statements with respect to the Company’s plans, objectives, expectations and intentions and other statements identified by words such as “may”, “could”, “would”, “should”, “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control).
L.G. Zangani, LLC provides financial public relations service to the Company. As such L.G. Zangani, LLC and/or its officers, agents and employees, receives remuneration for public relations and or other services in the form of monies, capital stock in the Company, warrants or options to purchase capital in the Company. The full disclaimer can be read here at http://www.zangani.com/disclaimer.
Contact:
Kevin Nally
Zangani Investor Community
9 Main Street
Flemington, NJ 08822
office@zangani.com
http://www.zangani.com
###
Contact
L.G. Zangani, LLC
Kevin Nally
908-788-9660
www.zangani.com
X 625
Kevin Nally
908-788-9660
www.zangani.com
X 625
Contact
Categories